Actively Recruiting
A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors
Led by Shanghai Pharmaceuticals Holding Co., Ltd · Updated on 2026-05-05
68
Participants Needed
22
Research Sites
155 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical study evaluated the efficacy and safety of T3011 in combination with PD-1/PD-L1 inhibitors in subjects with advanced solid tumors
CONDITIONS
Official Title
A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have advanced solid tumors
- Have at least one measurable lesion
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Expected survival longer than 12 weeks
- Meet laboratory test requirements
- Women of childbearing potential must have a negative pregnancy test before the first dose and use effective contraception from consent until 6 months after last dose
- Male subjects of childbearing potential must use effective contraception from consent until 6 months after last dose and agree not to donate sperm during this period
- Understand and voluntarily sign the informed consent form and are willing and able to comply with all study requirements
You will not qualify if you...
- Received other antitumor therapy within the specified time before the first dose
- History of other malignancies within the specified time before starting treatment
- History or evidence of high-risk cardiovascular disease at screening
- Persistent or active infection requiring intravenous antibiotics
- Autoimmune diseases or history of autoimmune diseases
- Known psychiatric disorders that may affect compliance
- Have pleural effusion, pericardial effusion, or ascites requiring puncture drainage before treatment or had such drainage recently
- Need systemic treatment with anti-HSV drugs during the study
- Received live or attenuated vaccines within the specified time before first dose or plan to receive such vaccines during the study
- Received any tumor vaccine in the past
- Major surgery within the specified time before first dose and not recovered from surgery-related adverse reactions or still in recovery, or plan major surgery during the study
- History of drug, drug abuse, or alcohol abuse within one year before consent
- Pregnant, breastfeeding, or planning to conceive during the study
- Investigator considers participation inappropriate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 22 locations
1
Anyang Cancer Hospital
Anyang, China
Actively Recruiting
2
The First Affiliated Hospital of Bengbu Medical University
Bengbu, China
Actively Recruiting
3
Hunan cancer hospital
Changsha, China
Actively Recruiting
4
Sichuan Cancer Hospital
Chengdu, China
Actively Recruiting
5
Dongguan People's Hospital
Dongwan, China
Actively Recruiting
6
Fujian Cancer Hospital
Fuzhou, China
Actively Recruiting
7
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, China
Actively Recruiting
8
The First Affiliated Hospital of Guangdong Pharmaceutical University
Guangzhou, China
Actively Recruiting
9
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
Actively Recruiting
10
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
Actively Recruiting
11
Harbin Medical University Cancer Hospital
Ha’erbin, China
Actively Recruiting
12
Shandong cancer hospital
Jinan, China
Actively Recruiting
13
Jiangxi cancer hospital
Nanchang, China
Actively Recruiting
14
Guangxi Medical University Affiliated Cancer Hospital
Nanning, China
Actively Recruiting
15
Shanghai East Hospital
Shanghai, China
Actively Recruiting
16
Shanghai Ninth People's Hospital
Shanghai, China
Actively Recruiting
17
Liaoning Cancer Hospital
Shenyang, China
Actively Recruiting
18
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
Shenzhen, China
Actively Recruiting
19
Shanxi Cancer Hospital
Taiyuan, China
Actively Recruiting
20
Tianjin cancer hospital
Tianjin, China
Actively Recruiting
21
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Actively Recruiting
22
Henan cancer hospital
Zhengzhou, China
Actively Recruiting
Research Team
Y
Ye Guo
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here